Abstract:Anticancer drugs used for systemic chemotherapy often exhibit off-target toxicity and uncontrolled drug release due to their lack of targeting. To improve the bioavailability of drugs and reduce side effects, we have developed a mixed micelle of nanomedicine composed of two prodrugs with surface modified monoclonal antibody for cancer therapy. In this system, Nimotuzumab was used as targeting ligands of the mixed micelles (named as DCMMs) that is composed of polymer-doxorubicin prodrug (abbreviated as PEG- b -P(GMA- ss -DOX)) and maleimide polyethylene glycol-chlorin e6 (abbreviated as Mal-PEG-Ce6). The mixed micelles modified with Nimotuzumab (named as NTZ-DCMMs) bind to overexpressed EGFR receptors on Hepatoma-22 (H22) cells. Disulfide bonds in PEG- b -P(GMA- ss -DOX) are disrupted in tumor microenvironment, inducing the reduction-responsive release of DOX and leading to tumor cell apoptosis. Simultaneously, Chlorin e6 (Ce6) produced plenty of singlet oxygen ( 1 O 2 ) under laser irradiation to kill tumor cells. In vivo biological distribution and antineoplastic effect experiments demonstrate that NTZ-DCMMs enhanced drug enrichment at tumor sites through targeting function of antibody, dramatically suppressing tumor growth and mitigating cardiotoxicity of drugs. All results prove that NTZ-DCMMs have the ability to actively target H22 cells and quickly respond to tumor microenvironment, which is expected to become an intelligent and multifunctional drug delivery carrier for efficient chemotherapy and photodynamic therapy of hepatoma. Statement of significance Anticancer drugs used for systemic chemotherapy often exhibit off-target toxicity due to their lack of targeting. Therefore, it's necessary to develop effective, targeted, and collaborative treatment strategies. We construct a mixed micelle of nanomedicine based on two polymer prodrugs and modified with monoclonal antibody on surface for cancer therapy. Under the tumor cell microenvironment, the disulfide bonds of polymer- ss -DOX were broken, effectively triggering DOX release. The photosensitizer Ce6 could generate a large amount of ROS under light, which synergistically promotes tumor cell apoptosis. By coupling antibodies to the hydrophilic segments of polymer micelles, drugs can be specifically delivered. Compared with monotherapy, the combination of chemotherapy and photodynamic therapy can significantly enhance the therapeutic effect of liver cancer.

Supplemental Figures 1 Through 14 from A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells

A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells.

A Dual-Responsive, Hyaluronic Acid Targeted Drug Delivery System Based on Hollow Mesoporous Silica Nanoparticles for Cancer Therapy.

Hybrid Nanoparticles for Drug Delivery and Bioimaging: Mesoporous Silica Nanoparticles Functionalized with Carboxyl Groups and a Near-Infrared Fluorescent Dye.

A Multifunctional Mesoporous Silica Nanocomposite for Targeted Delivery, Controlled Release of Doxorubicin and Bioimaging.

Transferrin-targeting Ph-Responsive and Biodegradable Mesoporous Silica Nanohybrid for Nitric Oxide-Sensitized Chemotherapy of Cancer

Ph-Sensitive Au-Bsa-Dox-Fa Nanocomposites for Combined Ct Imaging and Targeted Drug Delivery

Hyaluronidase-Responsive Mesoporous Silica Nanoparticles with Dual-Imaging and Dual-Target Function

A Self-Disguised Nanospy for Improving Drug Delivery Efficiency via Decreasing Drug Protonation

Smart MSN-Drug-Delivery System for Tumor Cell Targeting and Tumor Microenvironment Release

Hydroxylated Mesoporous Nanosilica Coated by Polyethylenimine Coupled with Gadolinium and Folic Acid: A Tumor-Targeted T(1) Magnetic Resonance Contrast Agent and Drug Delivery System.

Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.

Herceptin-Conjugated DOX-Fe 3 O 4 /P(NIPAM-AA-MAPEG) Nanogel System for HER2-Targeted Breast Cancer Treatment and Magnetic Resonance Imaging

Dual Responsive Mesoporous Silica Nanoparticles for Targeted Co-Delivery of Hydrophobic and Hydrophilic Anticancer Drugs to Tumor Cells.

Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer

Hyaluronic Acid-Modified and Doxorubicin-Loaded Gold Nanoparticles and Evaluation of Their Bioactivity

Ph-Responsive Nanoreservoirs Based on Hyaluronic Acid End-Capped Mesoporous Silica Nanoparticles for Targeted Drug Delivery.

Cancer Therapy and Fluorescence Imaging Using the Active Release of Doxorubicin from MSPs/Ni-LDH Folate Targeting Nanoparticles

A Nanomedicine Composed of Polymer- ss -DOX and Polymer-Ce6 Prodrugs with Monoclonal Antibody Targeting Effect for Anti-tumor Chemo-Photodynamic Synergetic Therapy

Cascade-Targeting of Charge-Reversal and Disulfide Bonds Shielding for Efficient DOX Delivery of Multistage Sensitive MSNs-COS-SS-CMC

Dual-targeted delivery system using hollow silica nanoparticles with H+-triggered bubble generating characteristic coated with hyaluronic acid and AS1411 for cancer therapy